Form 485BPOS T. Rowe Price Global
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20260225/A7ZZG22CZ22TA2CI222O2CZ2AT3JZZ2SZD82
Filed on: February 25, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VolitionRx Announces Pricing of $4.6 Million Public Offering
- Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
- Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
